The much anticipated AREDS2 trial has published its findings. The original AREDS (Age Related Eye Disease Study) found that the vitamin and mineral supplements which are now so commonly recommended to patients with early Age Related Macular Degeneration (AMD) were effective at slowing down the progression of the disease. The AREDS2 study looked at the benefits which might come from incorporating other supplements into the original tablets-
- docosahexaenoic acid (DHA)
- eicosapentaenoic acid (EPA)
It had been thought that incorporating these pigments which are found at the macular area, the area which is damaged in AMD would confer extra protection. The second two in the list are Omega 3 fatty acids which were also expected to help, but the study’s finding are that none of these extra ingredients are of any benefit over the original tablets’ formulation.